
Site burden is now measured through satisfaction surveys, in-the-moment check-ins, and adoption patterns, but each method catches a different moment, and the gaps between them decide whether teams can act before burden becomes risk.
The Crohn's & Colitis Foundation announced the launch of a dedicated Clinical Trials Community for inflammatory bowel diseases (IBD). The community is designed to educate patients, caregivers, and healthcare providers about the clinical trial process, its value, and how to address barriers that exist in enrollment.
The Crohn's & Colitis Foundation's Clinical Trial Community is made possible by support from AbbVie, Celgene Corporation, Genentech, Inc., and Takeda Pharmaceuticals U.S.A., Inc.
Read the full release






